Clinical Trial

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

Study acronym: MEGREZ
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-20
Trial Details
NCT Number NCT06300203
Lead Sponsor Beijing Tongren Hospital
Conditions Seasonal Allergic Rhinitis
Enrollment 120 participants
Start Date 2024-03-18
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-25